The Exchange has sought clarification from NGL Fine-Chem Limited for the quarter ended 31-Mar-2025 with respect to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. On basis of above the Company is required to clarify the following: -1. Financial results submitted in XBRL with discrepancies The response of the Company is awaited.
NGLFINE · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 1.5 pts more than Nifty Microcap 250 and 1.6 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
NSE has asked NGL Fine-Chem Limited to clarify discrepancies found in the financial results it submitted in XBRL format for the quarter ended 31 March 2025, under Regulation 33 of SEBI's Listing Obligations and Disclosure Requirements. The company has not yet responded to the exchange's query. No specific financial numbers or reasons for the discrepancy have been disclosed in the filing. This is a routine compliance-related clarification request rather than a formal regulatory action.
This is a procedural compliance flag and not a penalty or enforcement action. Investors should wait for the company's response to understand if there is any material issue with the reported numbers. Short-term sentiment may be mildly negative due to uncertainty, but no immediate impact on share price is expected unless the company fails to respond or reveals a substantive error.